Immunophotonics

Executive Summary

Immunophotonics is a clinical-stage biotechnology company developing a novel approach to interventional immuno-oncology. Its proprietary glycan polymer, IP-001, is designed to be injected at tumor sites following standard ablation procedures, where it captures antigens released from dying cancer cells and activates the immune system to mount a systemic anti-tumor response. This off-the-shelf, in situ vaccination strategy aims to turn routine local tumor ablation into a personalized, systemically active cancer immunotherapy without the need for ex vivo cell manipulation or complex manufacturing. The company's initial focus is on solid tumors amenable to ablation, such as liver, lung, and pancreatic cancers, addressing a large unmet need in converting local treatments into durable systemic immunity. The company has completed a Phase 1 dose-escalation trial demonstrating safety and early efficacy signals, including abscopal responses, and is currently preparing for a pivotal Phase 2/3 study. With a strong intellectual property portfolio and support from key opinion leaders in interventional oncology, Immunophotonics is well-positioned to disrupt the cancer immunotherapy landscape. If successful, IP-001 could become a standard addition to ablation procedures globally, significantly expanding the patient population that can benefit from immunotherapy. The company's capital-efficient approach and focus on an existing clinical workflow reduce barriers to adoption. However, the technology is still in early development with substantial execution risk.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 interim data for IP-001 in liver cancer50% success
• Q4 2026FDA orphan drug designation for IP-001 in hepatocellular carcinoma70% success
• Q2 2026Partnership announcement for manufacturing scale-up65% success